PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: GBT440

First Posted Date: 2017-04-14

Last Posted Date: 2023-07-18

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT03114540

Locations: 🇺🇸
OCRC, Orlando, Florida, United States
🇺🇸
University of Miami, Miami, Florida, United States

PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 10 mg dose MR formulations,10 mg dose of tofacitinib IR solution

First Posted Date: 2017-04-13

Last Posted Date: 2018-01-23

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT03112148

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer

Phase 1

Completed

Conditions: Neuroinflammation

Interventions: Drug: [11C]PF-06809247

First Posted Date: 2017-04-04

Last Posted Date: 2017-04-04

Lead Sponsor: Pfizer

Target Recruit Count: 7

Registration Number: NCT03100136

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Anylan Center, New Haven, Connecticut, United States

Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06865571
Drug: Placebo

First Posted Date: 2017-03-27

Last Posted Date: 2017-08-14

Lead Sponsor: Pfizer

Target Recruit Count: 17

Registration Number: NCT03092232

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Clostridium Difficile Vaccine Efficacy Trial

Phase 3

Completed

Conditions: Clostridium Difficile Infection

Interventions: Biological: Clostridium difficile vaccine
Biological: Placebo

First Posted Date: 2017-03-24

Last Posted Date: 2023-02-13

Lead Sponsor: Pfizer

Target Recruit Count: 17535

Registration Number: NCT03090191

Locations: 🇺🇸
Clinical Research Consulting, LLC, Milford, Connecticut, United States
🇺🇸
Bay Pines VA Healthcare System, Bay Pines, Florida, United States
🇺🇸
Multi-Specialty Research Associates, Inc., Lake City, Florida, United States

and more 415 locations

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Talazoparib
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2017-03-13

Last Posted Date: 2021-06-30

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT03077607

Locations: 🇲🇩
ARENSIA Exploratory Medicine Phase I Unit, PMSI Institute of Oncology, Chisinau, Moldova, Republic of
🇷🇺
"BioEq" LLC, Saint-Petersburg, Russian Federation
🇷🇺
I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation

and more 3 locations

Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions

Completed

Conditions: Arthritis, Rheumatoid

First Posted Date: 2017-03-08

Last Posted Date: 2020-10-22

Lead Sponsor: Pfizer

Target Recruit Count: 170

Registration Number: NCT03073109

Locations: 🇨🇴
Fundacion Valle del Lili, Cali, Colombia
🇨🇴
Fundacion Instituto de Reumatologia Fernando Chalem, Bogota, Cundinamarca, Colombia
🇨🇴
IDEARG, Bogota, Cundinamarca, Colombia

and more 10 locations

A Study of Talazoparib in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Talazoparib

First Posted Date: 2017-03-03

Last Posted Date: 2018-12-17

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT03070548

Locations: 🇭🇺
PRA Magyarorszag Kft, Fazis I-es Klinikai Farmakologiai Vizsgalohely, Budapest, Hungary

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

Phase 2

Completed

Conditions: Hemophilia A

Interventions: Biological: SB-525 (PF-07055480)

First Posted Date: 2017-02-23

Last Posted Date: 2024-07-30

Lead Sponsor: Pfizer

Target Recruit Count: 13

Registration Number: NCT03061201

Locations: 🇺🇸
UPMC Montefiore Clinical and Translational Research Center, Pittsburgh, Pennsylvania, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States

and more 19 locations

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Phase 3

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Lorlatinib
Drug: Crizotinib

First Posted Date: 2017-02-14

Last Posted Date: 2024-12-24

Lead Sponsor: Pfizer

Target Recruit Count: 296

Registration Number: NCT03052608

Locations: 🇺🇸
The William P. Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts, United States
🇺🇸
Ophthalmic Consultants of Boston Inc, Boston, Massachusetts, United States
🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

and more 136 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy